Ironwood Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ironwood Pharmaceuticals, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Deficient Aseptic Filling And Freeze Drying Hamstring Sandoz’s US Herceptin
Sandoz spoke to Generics Bulletin in the wake of confirming a recent complete response letter for its partnered biosimilar Herceptin candidate in the US.
BMS's Abecma Faces J&J Threat Despite Pivotal Success In Earlier Myeloma Setting
The US major’s CAR-T therapy is likely to win a label expansion to the large third-line-plus myeloma setting following positive Phase III data but a rival candidate from J&J could nab more of the market.
China Approves Two More Home-Grown COVID-19 Antivirals
Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.
- Other Names / Subsidiaries
- Microbia, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.